RESUMO
ABSTRACT Objective: To analyze the use of ivermectin as COVID-19 prevention method by the population of Mato Grosso in 2020. Methods: This is a home-based survey, carried out between September and October 2020, in 10 pole cities of the socioeconomic regions of State. The use of ivermectin was evaluated through the question: "Did you take ivermectin to prevent COVID-19?". Sociodemographic variables (sex, age group, education, family income), current work situation, being benefitted by government financial programs, as well as symptoms, seroprevalence of antibodies against SARS-CoV-2, and previous diagnosis of COVID-19 were evaluated. Prevalence and their associations were estimated using the chi-square test. Results: 4.206 individuals were evaluated for prevalence of ivermectin use; 58.3% of the individuals responded positively, this rate being higher in the municipalities of the western region of the state (66.6%). There was no significant difference between sexes, but the prevalence was higher among people aged 50-59 years (69.7%), who were white (66.5%), with complete higher education or more (68.8%) and higher family income (≥3 minimum wages-64.2%). The use of this drug was even higher among participants who considered their knowledge of the disease good or very good (65.0%), who reported having symptoms of COVID-19 (75.3%), and who had been previously diagnosed with the disease (91.2%). Conclusion: There was a high prevalence of use of ivermectin as a method to prevent covid-19 by the population of Mato Grosso, indicating the need for strategies to inform the population about the risks of off-label use of drugs and to combat the advertising of drugs that are ineffective against COVID-19.
RESUMO Objetivo: Analisar a utilização de ivermectina como prevenção da COVID-19 pela população de Mato Grosso em 2020. Métodos: Trata-se de um inquérito de base domiciliar, realizado entre setembro e outubro de 2020, em dez municípios-polos das regiões socioeconômicas do estado. O uso da ivermectina foi avaliado por meio da pergunta: "Tomou ivermectina para prevenir a COVID-19?". Foram avaliadas as variáveis sociodemográficas (sexo, faixa etária, escolaridade, renda familiar), a situação de trabalho atual, o recebimento de benefícios financeiros governamentais, bem como sintomas, a soroprevalência de anticorpos contra SARS-CoV-2 e o diagnóstico prévio de COVID-19. As estimativas de prevalência e suas associações foram realizadas por meio do teste χ2. Resultados: Foram analisados 4.206 indivíduos, e a prevalência de uso de ivermectina foi de 58,3%, sendo maior nos municípios da região Oeste (66,6%). Não houve diferença significativa entre os sexos, a prevalência foi maior na da faixa etária de 50-59 anos (69,7%), em pessoas brancas (66,5%), com ensino superior completo ou mais (68,8%) e maior renda familiar (≥3 salários-mínimos — 64,2%). A utilização do medicamento ainda foi maior entre os que consideraram seu conhecimento sobre a doença como bom ou muito bom (65,0%), entre os que referiram ter apresentado sintomas de COVID-19 (75,3%) e que foram diagnosticados com a doença previamente (91,2%). Conclusão: Verifica-se a elevada a prevalência do uso de ivermectina para a prevenção da COVID-19 pela população de Mato Grosso, indicando a necessidade de estratégias para informar a população sobre os riscos do uso off-label de medicamentos e combater a publicidade de medicamentos sem eficácia contra COVID-19.
RESUMO
Background/Aims@#Chronic psychological stress affects gastrointestinal physiology which may underpin alterations in the immune response and epithelial transport, both functions are partly regulated by enteric nervous system. However, its effects on enteric neuroplasticity are still unclear.This study aims to investigate the effects of chronic unpredictable psychological stress on intestinal motility and prominent markers of enteric function. @*Methods@#Adult male C57BL/6J mice were exposed to 19 day of unpredictable stress protocol schedule of social defeat and overcrowding. We investigated the effects on plasma corticosterone, food intake, and body weight. In vivo gastrointestinal motility was assessed by fecal pellet output and by whole-gastrointestinal transit (using the carmine red method). Tissue monoamine level, neural and glial markers, neurotrophic factors, monoamine signaling, and Toll-like receptor expression in the proximal and distal colon, and terminal ileum were also assessed. @*Results@#Following chronic unpredictable psychological stress, stressed mice showed increased food intake and body weight gain (P < 0.001), and reduced corticosterone levels (P < 0.05) compared to control mice. Stressed mice had reduced stool output without differences in water content, and showed a delayed gastrointestinal transit compared to control mice (P < 0.05). Stressed mice exhibited decreased mRNA expression of tyrosine hydroxylase (Th), brain-derived neurotrophic factor (Bdnf) and glial cell-derived neurotrophic factor (Gdnf), as well as Toll-like receptor 2 (Tlr2) compared to control (P < 0.05), only proximal colon. These molecular changes in proximal colon were associated with higher levels of monoamines in tissue. @*Conclusion@#Unpredictable psychological chronic stress induces region-specific impairment in monoamine levels and neuroplasticity markers that may relate to delayed intestinal transit.
RESUMO
The interface between the intestinal lumen and the mucosa is the location where the majority of ingested immunogenic particles face the scrutiny of the vast gastrointestinal immune system. Upon regular physiological conditions, the intestinal micro-flora and the epithelial barrier are well prepared to process daily a huge amount of food-derived antigens and non-immunogenic particles. Similarly, they are ready to prevent environmental toxins and microbial antigens to penetrate further and interact with the mucosal-associated immune system. These functions promote the development of proper immune responses and oral tolerance and prevent disease and inflammation. Brain-gut axis structures participate in the processing and execution of response signals to external and internal stimuli. The brain-gut axis integrates local and distant regulatory networks and super-systems that serve key housekeeping physiological functions including the balanced functioning of the intestinal barrier. Disturbance of the brain-gut axis may induce intestinal barrier dysfunction, increasing the risk of uncontrolled immunological reactions, which may indeed trigger transient mucosal inflammation and gut disease. There is a large body of evidence indicating that stress, through the brain-gut axis, may cause intestinal barrier dysfunction, mainly via the systemic and peripheral release of corticotropin-releasing factor. In this review, we describe the role of stress and corticotropin-releasing factor in the regulation of gastrointestinal permeability, and discuss the link to both health and pathological conditions.